Literature DB >> 1377274

Abnormalities of T lymphocyte subsets in Behçet's disease demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies.

A Kahan1, K Hamzaoui, K Ayed.   

Abstract

We assessed T cell subpopulations using 2-color flow cytometry with phycoerythrin conjugated anti-CD45RA and anti-CD29 and fluorescein conjugated anti-CD4 and anti-CD8 monoclonal antibodies, on peripheral blood lymphocytes from 19 patients with Behçet's disease (BD) and 18 healthy control subjects. The percentage of CD4+ cells was significantly lower in patients with BD (34 +/- 2%) than in control subjects (46 +/- 3%) (p less than 0.001). Among CD4+ cells, the percentage of suppressor-inducer (CD4+CD45RA+) cells was significantly lower in patients with BD (31 +/- 4%) than in control subjects (45 +/- 2%) (p less than 0.01), while the percentages of helper-inducer (CD4+CD29+) cells were similar in patients and controls. The percentage of CD8+ cells was significantly higher in patients with BD (36 +/- 2%) than in control subjects (26 +/- 2%) (p less than 0.001) involving both CD45RA+ and CD29+ subpopulations. Within CD4+ cells, the percentage of suppressor-inducer (CD4+CD45RA+) cells was significantly decreased in patients with active BD (26 +/- 3%) compared with control subjects (45 +/- 2%) (p less than 0.001), whereas in patients with inactive BD the difference was statistically insignificant. Our results suggest that the defective suppressive function in patients with active BD may be related to the decreased suppressor-inducer subpopulation (CD4+CD45RA+).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1377274

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Expression of Bcl-2 in inflammatory sites from patients with active Behçet's disease.

Authors:  K Hamzaoui; A Hamzaoui; L Zakraoui; A Chabbou
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

2.  Peripheral blood lymphocyte subsets in polymyalgia rheumatica.

Authors:  A Uddhammar; G Roos; B Näsman; S R Dahlqvist
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980

3.  Oligoclonal T cell expansions in patients with Behçet's disease.

Authors:  H Direskeneli; E Eksioglu-Demiralp; A Kibaroglu; S Yavuz; T Ergun; T Akoglu
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

4.  Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis.

Authors:  S Kurhan-Yavuz; H Direskeneli; N Bozkurt; Y Ozyazgan; T Bavbek; H Kazokoglu; E Eksioglu-Demiralp; G Wildner; M Diedrichs-Möhring; T Akoglu
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

5.  Flow cytometric characterisation of the "false naive" (CD45RA+, CD45RO-, CD29 bright+) peripheral blood T-lymphocytes in health and in rheumatoid arthritis.

Authors:  M Neidhart; F Pataki; J Schönbächler; P Brühlmann
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

6.  Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity.

Authors:  Antonina Accardo-Palumbo; Anna Rita Giardina; Francesco Ciccia; Angelo Ferrante; Alfonso Principato; Rosalia Impastato; Ennio Giardina; Giovanni Triolo
Journal:  Arthritis Res Ther       Date:  2010-06-03       Impact factor: 5.156

7.  The effect of vitamin D on clinical manifestations and activity of Behçet's disease.

Authors:  Nurşad Aslan; Kamile Demirci; Tuba Güler; Fulya Dörtbaş; Ebru Kale
Journal:  Postepy Dermatol Alergol       Date:  2017-02-07       Impact factor: 1.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.